IPLEDGE
The iPLEDGE program is a mandatory distribution program in the United States for isotretinoin (commonly sold under the trade names Roaccutane, Claravis, Absorica, Amnesteem, Myorisan, Sotret, or Zenatane), intended to prevent the use of the drug during pregnancy due to the high risk of birth defects (see Teratogenicity of isoretinoin). As of March 1, 2006, patients and their doctors and pharmacists are required by the U.S. Food and Drug Administration (FDA) to register and use a web site in order to receive this medication.
Wikipage redirect
primaryTopic
IPLEDGE
The iPLEDGE program is a mandatory distribution program in the United States for isotretinoin (commonly sold under the trade names Roaccutane, Claravis, Absorica, Amnesteem, Myorisan, Sotret, or Zenatane), intended to prevent the use of the drug during pregnancy due to the high risk of birth defects (see Teratogenicity of isoretinoin). As of March 1, 2006, patients and their doctors and pharmacists are required by the U.S. Food and Drug Administration (FDA) to register and use a web site in order to receive this medication.
has abstract
The iPLEDGE program is a manda ...... er to receive this medication.
@en
Link from a Wikipage to an external page
Wikipage page ID
Wikipage revision ID
733,615,717
alexa
launch date
screenshot
type
Regulatory/Government
hypernym
comment
The iPLEDGE program is a manda ...... er to receive this medication.
@en
label
IPLEDGE
@en
wasDerivedFrom
homepage
isPrimaryTopicOf
name
iPLEDGE Program
@en